Pulse Biosciences (NASDAQ:PLSE) Trading 5.3% Higher After Insider Buying Activity

Pulse Biosciences, Inc. (NASDAQ:PLSE) shot up 5.3% on Tuesday after an insider bought additional shares in the company. The stock traded as high as $20.54 and last traded at $20.18. 20,155 shares changed hands during trading, a decline of 90% from the average session volume of 200,547 shares. The stock had previously closed at $19.17.

Specifically, Director Robert W. Duggan purchased 55,256 shares of the stock in a transaction that occurred on Friday, December 13th. The stock was bought at an average cost of $17.18 per share, for a total transaction of $949,298.08. Following the completion of the transaction, the director now directly owns 42,328,717 shares in the company, valued at $727,207,358.06. This represents a 0.13 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Robert W. Duggan acquired 56,054 shares of the business’s stock in a transaction on Wednesday, December 11th. The shares were purchased at an average price of $17.35 per share, for a total transaction of $972,536.90. Following the transaction, the director now directly owns 42,228,057 shares of the company’s stock, valued at approximately $732,656,788.95. The trade was a 0.13 % increase in their ownership of the stock. The disclosure for this purchase can be found here.

Wall Street Analyst Weigh In

Separately, StockNews.com upgraded shares of Pulse Biosciences to a “sell” rating in a report on Thursday, December 12th.

Pulse Biosciences Trading Down 7.3 %

The stock has a 50 day moving average of $17.85 and a 200-day moving average of $16.56.

Pulse Biosciences (NASDAQ:PLSE) last released its earnings results on Wednesday, October 30th. The company reported ($0.21) earnings per share for the quarter. During the same period last year, the firm posted ($0.19) earnings per share.

Institutional Investors Weigh In On Pulse Biosciences

A number of institutional investors and hedge funds have recently added to or reduced their stakes in PLSE. Quest Partners LLC purchased a new position in Pulse Biosciences during the 2nd quarter worth $91,000. Rhumbline Advisers grew its position in shares of Pulse Biosciences by 6.7% during the 2nd quarter. Rhumbline Advisers now owns 25,729 shares of the company’s stock worth $288,000 after buying an additional 1,608 shares in the last quarter. Franklin Resources Inc. purchased a new position in shares of Pulse Biosciences during the third quarter valued at $378,000. Creative Planning raised its holdings in shares of Pulse Biosciences by 113.9% in the third quarter. Creative Planning now owns 21,910 shares of the company’s stock valued at $384,000 after acquiring an additional 11,667 shares in the last quarter. Finally, Barclays PLC lifted its stake in Pulse Biosciences by 361.4% in the third quarter. Barclays PLC now owns 30,306 shares of the company’s stock worth $530,000 after acquiring an additional 23,738 shares during the period. Institutional investors own 76.95% of the company’s stock.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.